How To Label Rx Drugs for Abuse And Dependence: US FDA Gives Directions For Consistency
Executive Summary
Labeling should include signs and symptoms of withdrawal as well as abuse-deterrent properties, draft guidance states.
You may also be interested in...
New Opioids May Need Comparative Effectiveness Data For Approval
Draft guidance says US FDA will consider product's benefit-risk balance relative to approved analgesics; it is particularly interested in comparative efficacy and safety data.
Will US FDA Remove Higher Strength Opioids From The Market?
Advisory committee members are divided on whether agency should restrict access to higher dose opioids, but most want option kept on the table.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.